Don't forget primary progressive aphasia for anti-amyloid drugs: An estimation of eligible patients from the Lausanne Memory Center registry.
Fiche du document
- doi: 10.1002/alz.13092
- issn: 1552-5260
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1002/alz.13092
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/37102466
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1552-5279
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_1AD93E64E8615
info:eu-repo/semantics/openAccess , CC BY-NC 4.0 , https://creativecommons.org/licenses/by-nc/4.0/
Sujets proches
TherapyCiter ce document
A. Hausmann et al., « Don't forget primary progressive aphasia for anti-amyloid drugs: An estimation of eligible patients from the Lausanne Memory Center registry. », Serveur académique Lausannois, ID : 10.1002/alz.13092
Métriques
Partage / Export
Résumé
The study recently published on the clinical effect of lecanemab in early Alzheimer's disease (AD) only includes patients with amnestic presentation. However, a significant portion of AD patients presents a non-amnestic phenotype of AD, such as primary progressive aphasia (PPA) and could benefit of rather than on lecanemab. Therefore, we conducted a 10-year retrospective study at the Leenaards Memory Center in Lausanne (Switzerland) to identify how many PPA patients would be eligible for lecanemab. Among 54 patients with PPA, we identified 11 (20%) eligible patients. Furthermore, almost half of the 18 patients with logopenic variant would be eligible for lecanemab treatment.